Developer docs
API playgroundTry for free, no card

Search company profiles

Prellis Biologics

Full company profile

uuid00004e3

Namestring
Prellis Biologics
Legal namestring
Prellis Biologics, Inc.
Websiteurl
prellisbio.com
Company typeenum
Private
Founded yearint
2016
Descriptiontext

Prellis Biologics is a private biotechnology company founded in 2016 by Dr. Melanie Matheu and headquartered in Berkeley, California. The company operates the EXIS (Externalized Human Immune System) platform, which combines proprietary 3D bioprinted lymph node organoids with AI/ML capabilities to discover and optimize fully human antibodies for therapeutic development. Underpinning the platform is a two-photon holographic 3D printing technology that achieves sub-micron resolution and can fabricate capillary-sized structures (5–10 microns in diameter) necessary to recapitulate authentic human immune responses in vitro. Prellis holds a granted U.S. patent (December 2019) covering functional human lymph node technology. In August 2022, Mike Nohaile (formerly CSO of Generate Biomedicines, SVP at Amgen, and Global Head of Molecular Diagnostics at Novartis) was appointed CEO; founder Melanie Matheu became CTO and retained a board seat.

The company commercializes its platform through multi-target drug discovery collaborations with large pharmaceutical companies, generating revenue via upfront payments, development and sales milestones, and royalties on licensed antibodies. Active pharma partnerships include Eli Lilly (announced September 23, 2025, flagship multi-target collaboration combining EXIS and AntiGen AI), Bristol Myers Squibb (January 2022), and Sanofi (March 2022). Prellis also sells Vascular Tissue Blanks — biocompatible vascularized scaffolds — as research products to academic and pharmaceutical laboratories, with reported users including UCSF, Johns Hopkins, UC Irvine, and Memorial Sloan Kettering. The company is concurrently developing an internal therapeutic pipeline across immunology and inflammation (TL1A, OX40, IL-11 targets), obesity and metabolic disorders (GIPR/GLP-1, GPR75), and oncology (CD3, STEAP1, SLC7A11). The September 2025 launch of the AntiGen AI platform extends the technology surface to AI-driven optimization of antibody efficacy, safety, and manufacturability.

Prellis is backed by approximately $64.5 million in total venture funding raised across a Series A ($8.7 million, Khosla Ventures, 2019), Series B ($14.5 million, Celesta Capital, December 2021), and Series C ($35 million, co-led by Celesta Capital and Avidity Partners, August 2022 at a $295 million pre-money valuation), with additional SOSV-related tranches continuing through 2025. Headcount is reported at 11–50 employees, and the company operates without disclosed revenue, consistent with an early-commercial-stage biotech whose value capture is anchored in milestone-based pharma partnerships and long-dated royalties on licensed programs.

Short descriptiontext

Prellis Biologics is a Berkeley-based private biotechnology company that uses 3D bioprinted human lymph node organoids combined with AI/ML (EXIS and AntiGen AI platforms) to discover and optimize fully human antibody therapeutics, partnering with Eli Lilly, Sanofi, and Bristol Myers Squibb.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersBerkeley, United States
HQ citystring
Berkeley
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
antibody discovery platform, 3D bioprinted organoids, human antibody therapeutics, lymph node organoid technology, AI-driven drug discovery
Industry5 codes
PRIMARYHLAAAIAB
Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAAIAJ
In Vitro Model Systems & Organoid Platforms (iPSC/organoids, microphysiological systems)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAAIAE
AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAAAAJ
Engineered Protein Therapeutics (de novo/AI-designed proteins, novel scaffolds)
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
SECONDARYHLAAAIAC
Protein Engineering & Directed Evolution Platforms (enzyme/therapeutic protein optimization)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
NAICS code2 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Biological Product (except Diagnostic) Manufacturing325414
SIC code1 code
  • Biological Products, (No Disgnostic Substances)2836
Product category
Therapeutic Antibody Discovery & Development
Social media profiles2 records
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model2 records
1Pharmaceutical Partnerships and Licensing
TypeLicensing Royalties
Description

Prellis enters into multi-target drug discovery collaborations with pharmaceutical companies, receiving upfront payments, development and sales milestones, and royalties on licensed antibodies.

prellisbio.com
2Collaboration and Option Agreements
TypeLicensing Royalties
Description

Strategic collaboration and licensing option agreements with pharma partners like Sanofi and Bristol Myers Squibb, generating upfront and milestone-based revenue.

prellisbio.com
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure
GTM typeB2B
B2B
Offering typeServices
Services
Brand1 of 3 records shown
1EXIS
Description

Externalized Human Immune System - a proprietary platform using 3D bioprinted lymph node organoids (LNOs) to recapture human immune biology for rapid antibody discovery.

prellisbio.com
+2 more records
Core offering1 text field

Prellis Biologics develops the EXIS (Externalized Human Immune System) platform, which combines 3D bioprinted lymph node organoids (LNOs) with AI/ML to rapidly discover fully human antibodies for therapeutic development. The company offers the AntiGen AI optimization platform for antibody maturation, Vascular Tissue Blanks for research applications, and a pipeline of therapeutic antibody programs in immunology & inflammation, obesity & metabolic disorders, and oncology, delivered through licensing and collaboration agreements with pharmaceutical partners.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 6 values shown
  • 300 human IgG antibodies generated against SARS-CoV-2 in under one month
+5 more records
Product overview1 text field

Prellis Biologics operates as a biotherapeutics company built around its proprietary EXIS (Externalized Human Immune System) platform, which integrates 3D bioprinted lymph node organoids (LNO) with AI/ML for antibody discovery and optimization. The platform is supported by the AntiGen AI system for rapid antibody maturation. The company offers Vascular Tissue Blanks as research products for pharmaceutical and academic labs. The therapeutic pipeline includes fully human antibody programs across Immunology & Inflammation (TL1A, OX40, IL-11 targets), Obesity & Metabolic Disorders (GIPR, GLP-1, Activin, GPR75 targets), and Oncology (CD3, STEAP1, SLC7A11 targets). Prellis generates antibody libraries from multiple donors, screens using AI-guided methods, and optimizes candidates for clinical development.

Product and service6 records
1EXIS (Externalized Human Immune System) Platform
CategoryAntibody Discovery Platform / Drug Discovery Technology
Description

A proprietary human immune system-based drug discovery platform that combines 3D bioprinted lymph node organoids (LNO) with AI/ML to rapidly discover and optimize fully human antibodies for therapeutic development. Delivered to pharmaceutical partners through multi-target collaboration agreements.

2Vascular Tissue Blanks
CategoryResearch Tools / Tissue Engineering Products
Description

Biocompatible 3D printed tissue scaffolds with high-resolution (sub-micron) vascular structures that support human tissue growth for drug testing, toxicology screening, and research applications. Sold to pharmaceutical and academic research labs.

3Therapeutic Antibody Pipeline (Immunology & Inflammation)
CategoryTherapeutic Antibody Programs
Description

Pipeline of fully human antibody therapeutics for immunology and inflammation indications, including programs against TL1A/IL-23, TL1A/OX40, TL1A/A4B7, OX40/IL-31, and IL-11 targets, developed and licensed to pharmaceutical partners.

4Therapeutic Antibody Pipeline (Obesity & Metabolic Disorders)
CategoryTherapeutic Antibody Programs
Description

Pipeline of fully human antibody therapeutics for obesity and metabolic disorders, including programs against GIPR/GLP-1, GIPR/GLP-1/Glucagon, GIPR/Activin, Activin RIIA/B, and GPR75 targets, developed and licensed to pharmaceutical partners.

5Therapeutic Antibody Pipeline (Oncology)
CategoryTherapeutic Antibody Programs
Description

Pipeline of fully human antibody therapeutics for oncology, including programs against CD3, STEAP1, and SLC7A11 targets, developed and licensed to pharmaceutical partners.

6AntiGen AI Platform
CategoryAI-driven Antibody Optimization
Description

AI-based optimization platform that rapidly matures antibody candidates into drug candidates with enhanced therapeutic efficacy, safety, and manufacturability. Used by Prellis and its pharmaceutical partners to refine and optimize antibody attributes.

Scale indicator9 records

Each record includes

Type, Value, Description, Source

Partnership3 partners
Strategic tierFlagshipTypeStrategic or Co-development PartnerAnnounced on2025-09-23
Description

Multi-target drug discovery and development collaboration to advance human antibody therapeutics. Prellis EXIS and AntiGen AI platforms combined with Lilly's research, development, and commercialization expertise. Prellis receives upfront payment, development and sales milestones, and royalties for licensed antibodies.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2022-03-22
Description

Collaboration and licensing option agreement for antibody discovery using Prellis EXIS platform.

3Bristol Myers Squibb
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2022-01-13
Description

Collaboration and license agreement for antibody development leveraging Prellis technology.

prellisbio.com
Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Vancouver-based antibody discovery platform that uses single-cell screening and AI to deliver lead candidates to pharma partners. Directly comparable to Prellis's EXIS offering of rapid, high-diversity antibody discovery against multi-target collaborations.

TypeDirect peer
Description

AI-driven generative biology company combining deep learning with a proprietary E. coli expression system for de novo antibody and protein design. Closely comparable to Prellis's combined AI + wet-lab approach to antibody engineering.

TypeDirect peer
Description

Leader in yeast display-based antibody discovery serving pharma through multi-target partnership deals. Comparable B2B antibody discovery business model and target-customer overlap with Prellis's EXIS platform.

TypeDirect peer
Description

AI-first protein design company creating novel therapeutics computationally and validating them experimentally. Directly comparable to Prellis's Bio AI strategy and a known prior employer of Prellis's CEO.

TypeDirect peer
Description

Machine-learning-guided antibody engineering platform combining wet-lab high-throughput synthesis with ML design loops. Comparable in integrating AI tightly with experimental antibody characterization.

6Atreca
TypeDirect peer
Description

Clinical-stage biotech leveraging immune response sequencing to discover novel antibody therapeutics. Comparable use of human immune biology for antibody discovery, though at a more advanced clinical stage.

TypeDirect peer
Description

Antibody-focused clinical-stage biotech developing multi-target therapeutics in oncology and autoimmune disease. Overlaps with Prellis's pipeline areas (e.g., TL1A, CD3) and antibody-discovery business model.

8Antiverse
TypeEmerging player
Description

Early-stage AI antibody design company focused on difficult-to-drug targets. Comparable to Prellis's positioning on hard target classes (e.g., GPCRs) but at a much earlier stage and scale.

TypeBroad incumbent
Description

Established antibody therapeutics company with broad pipeline and multiple marketed products. Comparable end-product focus on fully human mAbs, though at a vastly larger commercial scale than Prellis.

TypeBroad incumbent
Description

Large synthetic biology platform serving pharma and industrial biotech. Comparable use of engineered biological systems and AI/ML for R&D services, though much broader in scope than Prellis's antibody focus.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers7 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability5 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature6 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles13 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds14 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors15 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Prellis Biologics

Therapeutic Antibody Discovery & Developmentprellisbio.com

Prellis Biologics is a Berkeley-based private biotechnology company that uses 3D bioprinted human lymph node organoids combined with AI/ML (EXIS and AntiGen AI platforms) to discover and optimize fully human antibody therapeutics, partnering with Eli Lilly, Sanofi, and Bristol Myers Squibb.

What Prellis Biologics does

Prellis Biologics is a private biotechnology company founded in 2016 by Dr. Melanie Matheu and headquartered in Berkeley, California. The company operates the EXIS (Externalized Human Immune System) platform, which combines proprietary 3D bioprinted lymph node organoids with AI/ML capabilities to discover and optimize fully human antibodies for therapeutic development. Underpinning the platform is a two-photon holographic 3D printing technology that achieves sub-micron resolution and can fabricate capillary-sized structures (5–10 microns in diameter) necessary to recapitulate authentic human immune responses in vitro. Prellis holds a granted U.S. patent (December 2019) covering functional human lymph node technology. In August 2022, Mike Nohaile (formerly CSO of Generate Biomedicines, SVP at Amgen, and Global Head of Molecular Diagnostics at Novartis) was appointed CEO; founder Melanie Matheu became CTO and retained a board seat.

The company commercializes its platform through multi-target drug discovery collaborations with large pharmaceutical companies, generating revenue via upfront payments, development and sales milestones, and royalties on licensed antibodies. Active pharma partnerships include Eli Lilly (announced September 23, 2025, flagship multi-target collaboration combining EXIS and AntiGen AI), Bristol Myers Squibb (January 2022), and Sanofi (March 2022). Prellis also sells Vascular Tissue Blanks — biocompatible vascularized scaffolds — as research products to academic and pharmaceutical laboratories, with reported users including UCSF, Johns Hopkins, UC Irvine, and Memorial Sloan Kettering. The company is concurrently developing an internal therapeutic pipeline across immunology and inflammation (TL1A, OX40, IL-11 targets), obesity and metabolic disorders (GIPR/GLP-1, GPR75), and oncology (CD3, STEAP1, SLC7A11). The September 2025 launch of the AntiGen AI platform extends the technology surface to AI-driven optimization of antibody efficacy, safety, and manufacturability.

Prellis is backed by approximately $64.5 million in total venture funding raised across a Series A ($8.7 million, Khosla Ventures, 2019), Series B ($14.5 million, Celesta Capital, December 2021), and Series C ($35 million, co-led by Celesta Capital and Avidity Partners, August 2022 at a $295 million pre-money valuation), with additional SOSV-related tranches continuing through 2025. Headcount is reported at 11–50 employees, and the company operates without disclosed revenue, consistent with an early-commercial-stage biotech whose value capture is anchored in milestone-based pharma partnerships and long-dated royalties on licensed programs.

Prellis Biologics firmographics

Firmographics
Name
Prellis Biologics
Legal name
Prellis Biologics, Inc.
Website
https://prellisbio.com
Company type
Private
Founded year
2016
Operating status
Operating
Headcount range
51–100 employees
Short description
Prellis Biologics is a Berkeley-based private biotechnology company that uses 3D bioprinted human lymph node organoids combined with AI/ML (EXIS and AntiGen AI platforms) to discover and optimize fully human antibody therapeutics, partnering with Eli Lilly, Sanofi, and Bristol Myers Squibb.
Ownership category
akta.pro rank

Prellis Biologics industry classification

Industry
Product category
Therapeutic Antibody Discovery & Development
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Biological Product (except Diagnostic) Manufacturing (325414)
SIC
Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAAAIAB
Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAAIAJ
In Vitro Model Systems & Organoid Platforms (iPSC/organoids, microphysiological systems)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAAIAE
AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAAAAJ
Engineered Protein Therapeutics (de novo/AI-designed proteins, novel scaffolds)
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
SECONDARYHLAAAIAC
Protein Engineering & Directed Evolution Platforms (enzyme/therapeutic protein optimization)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)

Keywords

  • Antibody discovery platform
  • 3D bioprinted organoids
  • Human antibody therapeutics
  • Lymph node organoid technology
  • AI-driven drug discovery

Where Prellis Biologics is headquartered

Location

Headquarters

HQ city
Berkeley
HQ country
United States
HQ region
North America

Offices2 records

Markets served

Prellis Biologics business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure

Revenue model

  1. Pharmaceutical Partnerships and Licensing: Prellis enters into multi-target drug discovery collaborations with pharmaceutical companies, receiving upfront payments, development and sales milestones, and royalties on licensed antibodies.
  2. Collaboration and Option Agreements: Strategic collaboration and licensing option agreements with pharma partners like Sanofi and Bristol Myers Squibb, generating upfront and milestone-based revenue.

Go-to-market motion2 records

Distribution channels1 record

Marketing channels6 records

Prellis Biologics product offering

Product offering

Core offering

Prellis Biologics develops the EXIS (Externalized Human Immune System) platform, which combines 3D bioprinted lymph node organoids (LNOs) with AI/ML to rapidly discover fully human antibodies for therapeutic development. The company offers the AntiGen AI optimization platform for antibody maturation, Vascular Tissue Blanks for research applications, and a pipeline of therapeutic antibody programs in immunology & inflammation, obesity & metabolic disorders, and oncology, delivered through licensing and collaboration agreements with pharmaceutical partners.

Product overview

Prellis Biologics operates as a biotherapeutics company built around its proprietary EXIS (Externalized Human Immune System) platform, which integrates 3D bioprinted lymph node organoids (LNO) with AI/ML for antibody discovery and optimization. The platform is supported by the AntiGen AI system for rapid antibody maturation. The company offers Vascular Tissue Blanks as research products for pharmaceutical and academic labs. The therapeutic pipeline includes fully human antibody programs across Immunology & Inflammation (TL1A, OX40, IL-11 targets), Obesity & Metabolic Disorders (GIPR, GLP-1, Activin, GPR75 targets), and Oncology (CD3, STEAP1, SLC7A11 targets). Prellis generates antibody libraries from multiple donors, screens using AI-guided methods, and optimizes candidates for clinical development.

Differentiator

Problem solved

Functional benefit

Brands

  • EXIS: Externalized Human Immune System - a proprietary platform using 3D bioprinted lymph node organoids (LNOs) to recapture human immune biology for rapid antibody discovery.
  • EXIS (Externalized Immune System)
  • Vascular Tissue Blanks

Products and services

  • EXIS (Externalized Human Immune System) Platform A proprietary human immune system-based drug discovery platform that combines 3D bioprinted lymph node organoids (LNO) with AI/ML to rapidly discover and optimize fully human antibodies for therapeutic development. Delivered to pharmaceutical partners through multi-target collaboration agreements.
  • Vascular Tissue Blanks Biocompatible 3D printed tissue scaffolds with high-resolution (sub-micron) vascular structures that support human tissue growth for drug testing, toxicology screening, and research applications. Sold to pharmaceutical and academic research labs.
  • Therapeutic Antibody Pipeline (Immunology & Inflammation) Pipeline of fully human antibody therapeutics for immunology and inflammation indications, including programs against TL1A/IL-23, TL1A/OX40, TL1A/A4B7, OX40/IL-31, and IL-11 targets, developed and licensed to pharmaceutical partners.
  • Therapeutic Antibody Pipeline (Obesity & Metabolic Disorders) Pipeline of fully human antibody therapeutics for obesity and metabolic disorders, including programs against GIPR/GLP-1, GIPR/GLP-1/Glucagon, GIPR/Activin, Activin RIIA/B, and GPR75 targets, developed and licensed to pharmaceutical partners.
  • Therapeutic Antibody Pipeline (Oncology) Pipeline of fully human antibody therapeutics for oncology, including programs against CD3, STEAP1, and SLC7A11 targets, developed and licensed to pharmaceutical partners.
  • AntiGen AI Platform AI-based optimization platform that rapidly matures antibody candidates into drug candidates with enhanced therapeutic efficacy, safety, and manufacturability. Used by Prellis and its pharmaceutical partners to refine and optimize antibody attributes.

Quantifiable outcome

  • 300 human IgG antibodies generated against SARS-CoV-2 in under one month
  • +5 more outcomes

Companies that use Prellis Biologics

Customer profile

Named customers7 records

Segments3 records

Ideal customer profiles3 records

Prellis Biologics technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability5 records

Feature6 records

Prellis Biologics partnerships and signals

Strategic signal

Partnerships

Three partnerships are on record, tiered flagship and core.

  • Eli Lilly and CompanyflagshipStrategic or Co-development Partner · 23 September 2025Multi-target drug discovery and development collaboration to advance human antibody therapeutics. Prellis EXIS and AntiGen AI platforms combined with Lilly's research, development, and commercialization expertise. Prellis receives upfront payment, development and sales milestones, and royalties for licensed antibodies.
  • SanoficoreStrategic or Co-development Partner · 22 March 2022Collaboration and licensing option agreement for antibody discovery using Prellis EXIS platform.
  • Bristol Myers SquibbcoreStrategic or Co-development Partner · 13 January 2022Collaboration and license agreement for antibody development leveraging Prellis technology.

Scale indicators9 records

Recent moves6 records

Expansion highlights6 records

Prellis Biologics competitors and assessment

Company assessment

Direct peers

  • AbCellera Biologics: Vancouver-based antibody discovery platform that uses single-cell screening and AI to deliver lead candidates to pharma partners. Directly comparable to Prellis's EXIS offering of rapid, high-diversity antibody discovery against multi-target collaborations.
  • Absci: AI-driven generative biology company combining deep learning with a proprietary E. coli expression system for de novo antibody and protein design. Closely comparable to Prellis's combined AI + wet-lab approach to antibody engineering.
  • Adimab: Leader in yeast display-based antibody discovery serving pharma through multi-target partnership deals. Comparable B2B antibody discovery business model and target-customer overlap with Prellis's EXIS platform.
  • Generate Biomedicines: AI-first protein design company creating novel therapeutics computationally and validating them experimentally. Directly comparable to Prellis's Bio AI strategy and a known prior employer of Prellis's CEO.
  • BigHat Biosciences: Machine-learning-guided antibody engineering platform combining wet-lab high-throughput synthesis with ML design loops. Comparable in integrating AI tightly with experimental antibody characterization.
  • Atreca: Clinical-stage biotech leveraging immune response sequencing to discover novel antibody therapeutics. Comparable use of human immune biology for antibody discovery, though at a more advanced clinical stage.
  • Compass Therapeutics: Antibody-focused clinical-stage biotech developing multi-target therapeutics in oncology and autoimmune disease. Overlaps with Prellis's pipeline areas (e.g., TL1A, CD3) and antibody-discovery business model.

Emerging players

  • Antiverse: Early-stage AI antibody design company focused on difficult-to-drug targets. Comparable to Prellis's positioning on hard target classes (e.g., GPCRs) but at a much earlier stage and scale.

Broad incumbents

  • Genmab: Established antibody therapeutics company with broad pipeline and multiple marketed products. Comparable end-product focus on fully human mAbs, though at a vastly larger commercial scale than Prellis.
  • Ginkgo Bioworks: Large synthetic biology platform serving pharma and industrial biotech. Comparable use of engineered biological systems and AI/ML for R&D services, though much broader in scope than Prellis's antibody focus.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks5 records

Key highlights6 records

Customer concentration

Prellis Biologics social profiles

Digital presence

Prellis Biologics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Prellis Biologics leadership team

Management profile

Number of profiles

Profiles13 records

Prellis Biologics funding detail

Funding detail

Funding overview

Funding rounds14 records

Investors15 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Prellis Biologics M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Prellis Biologics

What does Prellis Biologics do?

Prellis Biologics develops the EXIS (Externalized Human Immune System) platform, which combines 3D bioprinted lymph node organoids (LNOs) with AI/ML to rapidly discover fully human antibodies for therapeutic development. The company offers the AntiGen AI optimization platform for antibody maturation, Vascular Tissue Blanks for research applications, and a pipeline of therapeutic antibody programs in immunology & inflammation, obesity & metabolic disorders, and oncology, delivered through licensing and collaboration agreements with pharmaceutical partners.

Is Prellis Biologics a public or private company?

Prellis Biologics is a private company. It is classified as venture growth investor backed and is currently operating.

When was Prellis Biologics founded?

Prellis Biologics was founded in 2016. It employs 51 to 100 people.

Where is Prellis Biologics based?

Prellis Biologics is headquartered in Berkeley, United States, in the North America region.

How does Prellis Biologics make money?

Two revenue lines are on record. Pharmaceutical Partnerships and Licensing is the primary driver. The others are collaboration and Option Agreements.

Who are Prellis Biologics's main competitors?

Direct peers on record are AbCellera Biologics, Absci, Adimab, Generate Biomedicines, BigHat Biosciences, Atreca and Compass Therapeutics. Antiverse is listed as an emerging player. Broad incumbents are Genmab and Ginkgo Bioworks.

Does Prellis Biologics have an API?

No public API is recorded for Prellis Biologics.

What industry is Prellis Biologics in?

Prellis Biologics's product category is Therapeutic Antibody Discovery & Development. Its primary akta.pro industry code is HLAAAIAB, Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering), with a secondary code of HLAAAIAJ, In Vitro Model Systems & Organoid Platforms (iPSC/organoids, microphysiological systems). Its NAICS code is 541714 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
EurekAlert!Prellis Bio Scaffold (2 of 2) (IMAGE)Prellis Biologics has launched TissueWorkshop, a web-based interface designed to help biologists and tissue engineers create 3D cell culture scaffolds. The platform enables the design of structures like the 'Dense Curves' scaffold, which features specific channel dimensions to optimize cellular nutrient and waste exchange. This tool aims to accelerate human tissue engineering research by providing an unbiased approach to three-dimensional architecture.YahooThe cutting edge: five exciting medical device startups to watchFive medical device startups are profiled, including Rubi Life's passive foetal monitor, Livongo's diabetes management system, Day Zero Diagnostics' rapid genomic sequencing, Prellis Biologics' 3D-printed tissues, and Clinical Science Systems' EEG service. Livongo raised $105m, and Day Zero aims to identify bacterial infections within five hours.IndiebioBiotherapeutics company Prellis Bio appoints new CEO, raises $35M series CPrellis Biologics appointed Michael Nohaile as its new CEO and raised $35 million in a Series C funding round co-led by Avidity Partners and Celesta Capital. This brings the company's total funding to $64.5 million, supporting the development of its two-photon holographic technology for drug discovery. Founder Dr. Melanie Matheu transitioned to Chief Technology Officer while retaining a board seat.VoxelMattersPrellis Biologics appoints new CEO and raises $35 millionPrellis Biologics appointed Michael Nohaile as CEO and raised $35 million in Series C funding co-led by Celesta Capital and Avidity Partners. The round brings total funding to $64.5 million, to be used for expanding its EXIS drug discovery platform. The company will also add two new board members.Venture Capital Access OnlinePrellis Biologics Appoints New CEO, Raises $35 Million in Series C Funding to Leverage Human Immune System Biology to De-Risk and Accelerate Therapeutics Drug Discovery and DevelopmentPrellis Biologics appointed Michael Nohaile as its new CEO and raised $35 million in Series C funding co-led by Celesta Capital and Avidity Partners. The capital will be used to expand the company's EXIS platform, which leverages human immune system biology to accelerate drug discovery. This brings Prellis Bio’s total funding to date to $64.5 million.FinSMEsPrellis Biologics Raises $35M in Series C FundingPrellis Biologics, a biotherapeutics company based in San Francisco, raised $35 million in Series C funding, bringing its total funding to $64.5 million. The funds will be used to expand its proprietary immune system-based drug discovery platform, EXIS™, and the company is involved in collaborations with Sanofi and Bristol Myers Squibb.BioSpacePrellis Biologics Announces Collaboration and License Agreement with Bristol Myers SquibbPrellis Biologics announced a multi-target drug discovery collaboration and licensing agreement with Bristol Myers Squibb. The partnership utilizes Prellis’ EXIS platform to generate human antibody libraries for select targets, with Prellis receiving an undisclosed up-front payment and potential milestone royalties.Business Wire BlogPrellis Biologics Announces Collaboration and License Agreement with Bristol Myers SquibbPrellis Biologics announced a multi-target drug discovery collaboration and license agreement with Bristol Myers Squibb utilizing its EXIS platform. Under the terms of the deal, Prellis will receive an undisclosed up-front payment and funding for research activities in exchange for generating human antibody libraries for select targets. This partnership aims to leverage Prellis' technology to break tolerance mechanisms and create high-affinity human antibodies targeting human proteins.ZapierPrellis Biologics raises $14.5M, debuts a ‘human immune system’ in a dishPrellis Biologics raised $14.5 million in a Series B round led by Celesta Capital, debuting EXIS, a lab-grown human lymph node organoid. The company plans to use the platform for antibody drug development, with partnerships with five drug companies. It aims to move from R&D to product focus, potentially bringing an antibody treatment to clinic.TechCrunchPrellis Biologics raises $14.5M, debuts a ‘human immune system’ in a dishPrellis Biologics, a San Francisco-based tissue engineering firm, closed a $14.5 million Series B round led by Celesta Capital and existing investor Khosla Ventures, with participation from SOSV IndieBio. The company, which previously printed vascular scaffolds, debuted EXIS, a lab-grown human lymph node organoid used to model immune responses and generate antibody candidates. CEO Melanie Matheu said the company is moving toward product focus and drug partnerships.